NCT05500508 - Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

December 12, 2024

Study Completion Date

December 12, 2024

Conditions

CancerSolid TumorSolid CarcinomaAdvanced CancerDIPG Brain TumorOvary CancerBreast CancerPapillary Thyroid CancerHead and Neck CancerGastric CancerNsclcMesotheliomas PleuralMesothelioma PeritoneumEsophageal CancerDiffuse Midline Glioma, H3 K27M-MutantEndometrial CancerCervical CancerMelanomaColorectal CancerGlioma, Malignant

Interventions

DRUG

AMXT1501

AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules

DRUG

DFMO

DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.

Trial Locations (7)

32224

Mayo Clinic - Florida, Jacksonville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55905

Mayo Clinic - Minnesota, Rochester

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic - Arizona, Phoenix

98109

Fred Hutch Cancer Center - Seattle Cancer Care Alliance, Seattle

Unknown

Kids Cancer Centre, Sydney